Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP‑Ribose) polymerase inhibitors against BRCA1/2 wild‑type ovarian cancer
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer - ScienceDirect
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer | Clinical Cancer Research
Lynparza Olaparib 150mg at Rs 315000/box | Lynparza | ID: 2487382288
Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer? - ScienceDirect
An Overview of PARP Inhibitors for the Treatment of Breast Cancer | SpringerLink
Olanib Tablets (Olaparib), टैबलेट्स - Lancer Health Care, New Delhi | ID: 20611805133
A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes - European Journal of Cancer
An Overview of PARP Inhibitors for the Treatment of Breast Cancer | SpringerLink
PDF) Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study
Olanib medicine 50mg Olaparib treats ovarian cancer - Price Olanib - INDEX CHINA Medicine
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Ca
An Overview of PARP Inhibitors for the Treatment of Breast Cancer | SpringerLink
Cancers | Free Full-Text | Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes | HTML
Cancers | Free Full-Text | Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer | HTML
Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP‑Ribose) polymerase inhibitors against BRCA1/2 wild‑type ovarian cancer
IJMS | Free Full-Text | Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy | HTML
Cancers | Free Full-Text | Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes | HTML
Role of PARP Inhibitors in BRCA-Related Malignancies
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database - The Lancet Haematology
Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer? - ScienceDirect
Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer? - ScienceDirect
Olanib medicine 50mg Olaparib treats ovarian cancer - Price Olanib - INDEX CHINA Medicine
